Information  X 
Enter a valid email address

Verona Pharma plc (VRP)

  Print      Mail a friend

Friday 17 January, 2020

Verona Pharma plc

Holding(s) in Company TR-1: Standard form for notification of major holdings

Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Verona Pharma plc
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameArix Bioscience plc
City and country of registered office (if applicable) 
4. Full name of shareholder(s) (if different from 3.)v
Name 
City and country of registered office (if applicable) 
5. Date on which the threshold was crossed or reachedvi:16 January 2020
6. Date on which issuer notified (DD/MM/YYYY):16 January 2020
7. Total positions of person(s) subject to the notification obligation
 % of voting rights
attached to shares
(total of 8. A)
% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in %
(8.A + 8.B)
Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached3.2% 3.2%105,326,638
Position of previous notification (if
applicable)
4.5% 4.5% 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct
(Art 9 of Directive
2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive
2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive
2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive
2004/109/EC) (DTR5.2.1)
GB00BYW2KH801,290,3522,110,0001.2%2.0%
     
     
SUBTOTAL 8. A3,400,3523.2%
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if
the instrument is
exercised/converted.
% of voting rights
     
     
     
  SUBTOTAL 8. B 1  
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
      
      
      
   SUBTOTAL 8.B.2  


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
 
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Arix Bioscience plc3.2%  3.2%
Arix Bioscience Holdings Limited1.2% directly 1.2% directly
Arthurian Life Sciences SPV GP Limited for and on behalf of The Wales Life Sciences Investment Fund LP2.0% indirectly 2.0% indirectly
    
    
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
 


Place of completionLondon, United Kingdom
Date of completion17 January 2020

a d v e r t i s e m e n t